Carmat To Launch Total Artificial Heart In Early 2021
Executive Summary
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
You may also be interested in...
News We’re Watching: Self-Powered Pacemakers, Artificial Hearts, And More
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. Chinese researchers are working on a self-powered pacemaker, Carmat updated its artificial heart progress, a trial validates Smith & Nephew's Regeneten implant in shoulder surgery, experts back intravascular IVUS in peripheral interventions, and Spectral AI launches a new trial of its AI for burn evaluation.
Pivotal Trial Of Carmat’s Total Artificial Heart Delayed
Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.
FDA Updates Class I Recall Alert For SynCardia's Bridge-To-Transplant System
SynCardia Systems' Freedom Driver System was subject to a class I recall last year, and now US FDA has updated its concerns about a component of the firm's Temporary Total Artificial Heart based on post-approval study data, and is asking that malfunctioning drivers be returned to the manufacturer.